Filtered By:
Condition: Thrombosis
Drug: Estradiol
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 61 results found since Jan 2013.
Stroke and Etonogestrel/Ethinyl Estradiol Ring (NuvaRing): Clinical, Radiological, and Prognostic Features. (P2.012)
Conclusions: In this largest case series of NuvaRing associated stroke to date, approximately half of the strokes are venous and half are arterial. Stroke typically occurred within the first year of use, and as soon as 2 weeks after NuvaRing initiation.Disclosure: Dr. Piran has nothing to disclose. Dr. Balucani has nothing to disclose. Dr. Tark has nothing to disclose. Dr. Adler has nothing to disclose. Dr. Levine has received personal compensation in an editorial capacity for MedLink. Dr. Levine has received royalty payments as editor of a book.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Piran, P., Balucani, C., Tark, B., Adler, Z., Levine, S. Tags: Cerebrovascular Disease and Interventional Neurology I Source Type: research
Hypercoagulability and Migraine
BackgroundA growing body of literature suggests that migraineurs, particularly those with aura, have an increased risk for ischemic stroke, but not via enhanced atherosclerosis. The theory that micro‐emboli induced ischemia provokes cortical spreading depression (ie, symptomatic aura) in migraineurs but transient ischemic attacks in others highlights a potential role for hypercoagulability as a link between migraine (with aura) and stroke.
AimOur objective is to summarize the literature evaluating the association of migraine with various acquired or inheritable thrombophilic states, including those related to elevated es...
Source: Headache: The Journal of Head and Face Pain - February 8, 2017 Category: Neurology Authors: Gretchen E. Tietjen, Stuart A. Collins Tags: Headache Currents Source Type: research
Hypercoagulability and Migraine.
Abstract
BACKGROUND: A growing body of literature suggests that migraineurs, particularly those with aura, have an increased risk for ischemic stroke, but not via enhanced atherosclerosis. The theory that micro-emboli induced ischemia provokes cortical spreading depression (ie, symptomatic aura) in migraineurs but transient ischemic attacks in others highlights a potential role for hypercoagulability as a link between migraine (with aura) and stroke.
AIM: Our objective is to summarize the literature evaluating the association of migraine with various acquired or inheritable thrombophilic states, including tho...
Source: Headache - February 8, 2017 Category: Neurology Authors: Tietjen GE, Collins SA Tags: Headache Source Type: research
HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
Abstract
ABSTRACT Hormone replacement therapy (HRT) remains the gold standard for treatment of climacteric symptoms in menopausal women; it is relatively safe in healthy subjects for at least 5 years, provided it had been initiated before the age of 60 years and/or within 10 years from menopause. Estrogen probably adds some cardioprotection, that can, however, be obscured by progestogens, especially medroxyprogesterone acetate (MPA). Oral HRT is associated with an increased risk of venous thromboembolism (VTE), gallbladder disease and possibly stroke. The increased occurrence of all these events can be prevented b...
Source: Climacteric - July 19, 2013 Category: Geriatrics Authors: L'hermite M Tags: Climacteric Source Type: research
Managing menopause.
Authors: Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W
Abstract
OBJECTIVE: To provide updated guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor or urogenital symptoms and on considerations related to cardiovascular disease, breast cancer, urogynaecology, and sexuality.
OUTCOMES: Lifestyle...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 2, 2014 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research
In recently postmenopausal women, HRT reduced a composite of death, MI, or heart failure at 10 years.
CONCLUSION In recently postmenopausal women, hormone replacement therapy reduced a composite of death, myocardial infarction, or heart failure after 10 years of therapy and an additional 6 years of follow-up.Hormone replacement therapy (HRT) vs no HRT in recently postmenopausal women†OutcomesEvent ratesAfter 10 y of therapyHRTNo HRTRRR (95% CI)NNT (CI)Death, MI, or HF‡3.2%6.5%50% (11 to 72)31 (22 to 144)At 16 yDeath, MI, or HF§6.6%11%37% (4 to 59)26 (17 to 251)†HF = heart failure; MI = myocardial infarction; other abbreviations defined in Glossary. RRR, NNT, and CI calculated from event rates and hazard ratios in ar...
Source: Annals of Internal Medicine - February 19, 2013 Category: Internal Medicine Authors: Cheung AM Tags: Ann Intern Med Source Type: research
The Case Files: Unusual Headache
By Al-Hashimi, Siddhartha DO; Leavens, John MD
A 23-year-old woman with a history of migraine headaches presented to the emergency department for a different-than-usual headache. She had a six-day history of intermittent headaches. The onset was at rest, and there was no history of trauma.
The headache was located behind her left eye, and it radiated into the posterior portion of her head. She characterized it as being 8/10 in intensity. Bright lights were reported as an exacerbating factor. The headache was associated with nausea and multiple episodes of emesis. She had 10 episodes of vomiting the evening prior to arri...
Source: The Case Files - June 5, 2014 Category: Emergency Medicine Tags: Blog Posts Source Type: research
Association of genetically predicted serum estradiol with risk of thromboembolism in men: A mendelian randomization study
CONCLUSIONS: Genetically predicted estradiol was inversely associated with risk of thromboembolism and ischemic stroke in men. The ratio between testosterone and estradiol, determined by aromatase (CYP19A1) activity, may contribute to the overall impact of sex steroids on thromboembolism in men.PMID:33705547 | DOI:10.1210/clinem/dgab164
Source: The Journal of Clinical Endocrinology and Metabolism - March 11, 2021 Category: Endocrinology Authors: Maria Nethander Johan Quester Liesbeth Vandenput Claes Ohlsson Source Type: research
CEE Raises Venous Thrombosis Risk vs Estradiol for Oral HRTCEE Raises Venous Thrombosis Risk vs Estradiol for Oral HRT
There was also a trend of increased MI risk but no signal of increased risk for ischemic stroke in the observational look at ischemic risk factors in women on HRT. Heartwire
Source: Medscape Today Headlines - October 1, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news
Cardiovascular highlights from non-cardiology journals
Estrogen formulations have differing cardiovascular risk profile Ever since the publication of the Women's Health Initiative randomized trial that demonstrated clinical harm associated with use of conjugated equine estrogens, providers have been left in a challenging position in balancing the risk of these therapies against their benefit in treatment of menopausal symptoms. In the present study, the authors examined cardiac safety of oral conjugated equine estrogen vs. oral estradiol in a population-based case control study of post-menopausal women. Cases of venous thrombosis (n=68), myocardial infarction (n=67) or ischemi...
Source: Heart - May 19, 2014 Category: Cardiology Authors: Bradley, S. M. Tags: Journal scan Source Type: research
Low-dose oral contraceptive-induced acute myocardial infarction.
CONCLUSION: Low-dose OCs may also be responsible for acute MI even in a very young female without any cardiovascular risk factors. Therefore, the clinicians should be aware of this mortal events during follow-up of the patient using OCs.
PMID: 27608962 [PubMed - as supplied by publisher]
Source: The European Journal of Contraception and Reproductive Health Care - September 8, 2016 Category: Reproduction Medicine Authors: Aslan AN, Süygün H, Sivri S, Keleş T Tags: Eur J Contracept Reprod Health Care Source Type: research
Estrogen Receptor Control of Atherosclerotic Calcification and Smooth Muscle Cell Osteogenic Differentiation.
CONCLUSIONS: We have demonstrated that E2 can drive calcification in advanced atherosclerotic lesions by promoting the differentiation of VSMC to osteoblast-like cells, a process which is augmented by inhibition of estrogen receptor alpha or ERβ activity.
PMID: 28473445 [PubMed - as supplied by publisher]
Source: Arteriosclerosis, Thrombosis and Vascular Biology - May 4, 2017 Category: Cardiology Authors: McRobb LS, McGrath KCY, Tsatralis T, Liong EC, Tan JTM, Hughes G, Handelsman DJ, Heather AK Tags: Arterioscler Thromb Vasc Biol Source Type: research
Transgender venous thrombosis
A 53-year-old male-to-female transgender patient on cross-sex hormone replacement therapy (CSHT), estradiol 8 mg daily, presented to the emergency department (ED) with acute-onset headache and left visual field disturbances after a recent mechanical fall with head trauma. The medical history was notable for hyperlipidemia. There was no personal or family history of clotting disorders and no history of tobacco use.
Source: Neurology Clinical Practice - December 11, 2017 Category: Neurology Authors: Opaskar, A., Scharf, E. L., Chilungu, M. W., Kelly, A. G. Tags: All Cerebrovascular disease/Stroke, Cerebral venous thrombosis Case Source Type: research
Transdermal estradiol for the management of refractory uremic bleeding.
CONCLUSION: Patients who are refractory to routine interventions for uremic bleeding may benefit from transdermal estrogen despite the limited data. Extended therapy with low-dose transdermal estrogen (≤50 μg daily) may provide a hemostatic benefit that outweighs thrombotic risk.
PMID: 29691259 [PubMed - in process]
Source: American Journal of Health-System Pharmacy : AJHP - April 25, 2018 Category: Drugs & Pharmacology Authors: Gonzalez J, Bryant S, Hermes-DeSantis ER Tags: Am J Health Syst Pharm Source Type: research
Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development
Cancer J. 2022 May-Jun 01;28(3):196-203. doi: 10.1097/PPO.0000000000000598.ABSTRACTSeveral formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure bo...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Abbie J Laing Louise Newson James A Simon Source Type: research
